Table 1 IC50 values of compounds against HepG2 cells
Tgel
Hgel
Compound
IC50/nM
Compound
IC50/nM
Taxol
Taxol + Dexa
Taxol-SA
Dex-FFFK(Taxol)E
Dex-FFFK (Taxol)E-ss-EE
47.3 ꢁ 8.2
47.0 ꢁ 5.7
188.8 ꢁ 14.5
96.4 ꢁ 27.2
75.8 ꢁ 19.0
HCPT
HCPT + Dexa
HCPT-GA
Dex-FFFK(HCPT)E
Dex-FFFK (HCPT)E-ss-EE
98.6 ꢁ 7.1
142.6 ꢁ 9.0
97.8 ꢁ 5.6
333.2 ꢁ 28.2
182.8 ꢁ 12.4
a
Mixed in equal molar (n = 3), IC50 values of other Dex-derivatives are higher than 100 mM.
PBS buffer solutions existed in both forms, as shown in
Notes and references
the ESI.w14 This result strongly indicated that hydrogels of
HCPT could help stabilize lactone forms of HCPT derivatives,
which might overcome HCPT’s shortcomings. This phenomenon
will be further studied in detail in the near future.
1 Y. Q. Shen, E. L. Jin, B. Zhang, C. J. Murphy, M. H. Sui, J. Zhao,
J. Q. Wang, J. B. Tang, M. H. Fan, E. Van Kirk and
W. J. Murdoch, J. Am. Chem. Soc., 2010, 132, 4259; S. Y. Kim
and Y. M. Lee, Biomaterials, 2001, 22, 1697; C. B. Packhaeuser,
J. Schnieders, C. G. Oster and T. Kissel, Eur. J. Pharm. Biopharm.,
2004, 58, 445; X. Zhang, J. K. Jackson and H. M. Burt, Int.
J. Pharm., 1996, 132, 195; Y. Luo and G. D. Prestwich, Bioconju-
gate Chem., 1999, 10, 755; N. I. Marupudi, J. E. Han, K. W. Li,
V. M. Renard, B. M. Tyler and H. Brem, Expert Opin. Drug Saf.,
2007, 6, 609.
2 F. Zhao, M. L. Ma and B. Xu, Chem. Soc. Rev., 2009, 38, 883.
3 R. Cherif-Cheikh, F. Bismuth, M. L. Torres, R. Alloza,
M. T. Bosch, M. Montes, E. Fuster, J. Valles, J. A. Cordero,
C. Peraire, R. Obach and R. Antonijoan, Proc. Int. Symp. Controlled
Release Bioact. Mater., 1998, 25, 798.
4 B. G. Xing, P. L. Ho, C. W. Yu, K. H. Chow, H. W. Gu and B. Xu,
Chem. Commun., 2003, 2224.
5 B. G. Xing, C. W. Yu, K. H. Chow, P. L. Ho, D. G. Fu and B. Xu,
J. Am. Chem. Soc., 2002, 124, 14846.
6 Y. Gao, Y. Kuang, Z. F. Guo, Z. H. Guo, I. J. Krauss and B. Xu,
J. Am. Chem. Soc., 2009, 131, 13576.
7 H. M. Wang, C. H. Yang, L. Wang, D. L. Kong, Y. J. Zhang and
Z. M. Yang, Chem. Commun., 2010, 46, 4439.
8 J. C. Tiller, Angew. Chem., Int. Ed., 2003, 42, 3072.
9 P. K. Vemula, G. A. Cruikshank, J. M. Karp and G. John, Bioma-
terials, 2009, 30, 383; Z. M. Yang, G. L. Liang, M. L. Ma,
A. S. Abbah, W. W. Lu and B. Xu, Chem. Commun., 2007, 843;
S. K. Maji, M. H. Perrin, M. R. Sawaya, S. Jessberger, K. Vadodaria,
R. A. Rissman, P. S. Singru, K. P. R. Nilsson, R. Simon,
D. Schubert, D. Eisenberg, J. Rivier, P. Sawchenko, W. Vale and
R. Riek, Science, 2009, 325, 328; S. K. Maji, D. Schubert, C. Rivier,
S. Lee, J. E. Rivier and R. Riek, PLoS Biol., 2008, 6, 240; S. Bhuniya,
Y. J. Seo and B. H. Kim, Tetrahedron Lett., 2006, 47, 7153;
S. Bhuniya, S. M. Park and B. H. Kim, Org. Lett., 2005, 7, 1741;
X. M. Li, J. Y. Li, Y. Gao, Y. Kuang, J. F. Shi and B. Xu, J. Am.
Chem. Soc., 2010, 132, 17707.
Next, we evaluated the activity of the compounds by treating
HepG2 cells at serials of concentrations (Table 1). After 48 hours
of incubation with the cells, Taxol and HCPT exhibited IC50
values of 47.3 and 98.6 nM, respectively. The free Dex and its
conjugates without anti-cancer drugs showed no inhibitions on
HepG2 cells at the concentration of 100 mM. Interestingly, the
combination of 1 equivalent of free Dex did not improve Taxol’s
activity and slightly decreased HCPT’s activity: IC50 values of
Taxol and HCPT were 47.0 and 142.6 nM, respectively. This
observation might account for the fact that Dex could reduce the
side effects of anti-cancer drugs during chemotherapy, which will
be further studied in an in vivo experiment in the future. Gelators
of Dex-FFFK(Taxol)E and Dex-FFFK(HCPT)E possessed IC50
values of 96.4 and 333.2 nM, respectively, which were 2 to 3 times
higher than those of Taxol + Dex and HCPT + Dex. Precursors
of gelators Dex-FFFK(Taxol/HCPT)E-ss-EE exhibited IC50
values of 75.8 and 182.8 nM, which were comparable to Taxol +
Dex and HCPT + Dex, respectively. These results indicated that
the combination of Dex with the anti-cancer drugs Taxol and
HCPT might reduce side effects of anti-cancer drugs during
chemotherapy while the activity of anti-cancer drugs was conserved
in the precursors and hydrogelators. These properties confer the
great potentials for our hydrogel system to be used as a co-delivery
system for the treatment of cancers.
In summary, we successfully developed a co-delivery hydrogel
system composed of two complementary anti-cancer drugs,
which might be applied in the cavity after surgical tumor
removal for the long-term release of anti-cancer drugs. The
stability of anti-cancer drugs was greatly improved in hydrogels,
and original drug molecules could be slowly released by ester
bond hydrolysis. We believe that the combination of multiple
complementary drugs in one hydrogelator will lead to a novel
co-delivery system for the treatment of different diseases.
Future studies will focus on the development of simpler
hydrogelators based on anti-cancer drugs and more stable
hydrogels that can facilitate the large-scale preparation of
drug derivatives and practical application. The in vivo stability
of hydrogels and release profiles of anti-cancer drugs will also
be studied.
10 M. G. Kris, R. J. Gralla, R. A. Clark, L. B. Tyson and S. Groshen,
Cancer, 1987, 60, 2816; A. H. Schinkel, E. Wagenaar, L. van
Deemter, C. A. Mol and P. Borst, J. Clin. Invest., 1995, 96, 1698.
11 H. M. Willemen, L. de Smet, A. Koudijs, M. C. A. Stuart,
I. Heikamp-de Jong, A. T. M. Marcelis and E. J. R. Sudholter,
Angew. Chem., Int. Ed., 2002, 41, 4275.
12 M. Reches and E. Gazit, Science, 2003, 300, 625; R. V. Ulijn and
A. M. Smith, Chem. Soc. Rev., 2008, 37, 664; E. T. Pashuck and
S. I. Stupp, J. Am. Chem. Soc., 2010, 132, 8819; X. H. Yan,
P. L. Zhu and J. B. Li, Chem. Soc. Rev., 2010, 39, 1877.
13 C. H. Ren, Z. J. Song, W. T. Zheng, X. M. Chen, L. Wang,
D. L. Kong and Z. M. Yang, Chem. Commun., 2010, 46, 1619.
14 See the ESIw.
15 L. Trynda-Lemiesz, Bioorg. Med. Chem., 2004, 12, 3269.
16 H. G. Lerchen, J. Baumgarten, K. von dem Bruch, T. E. Lehmann,
M. Sperzel, G. Kempka and H. H. Fiebig, J. Med. Chem., 2001,
44, 4186; A. Shenderova, T. G. Burke and S. P. Schwendeman,
Pharm. Res., 1999, 16, 241.
c
This journal is The Royal Society of Chemistry 2012
Chem. Commun., 2012, 48, 395–397 397